<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Mirabegron: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Mirabegron: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Mirabegron: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="86611" href="/d/html/86611.html" rel="external">see "Mirabegron: Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="131271" href="/d/html/131271.html" rel="external">see "Mirabegron: Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F15167819"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Myrbetriq</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52871458"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>Myrbetriq</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F14585338"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Beta<sub>3</sub> Agonist</li></ul></div>
<div class="block doa drugH1Div" id="F14965739"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e512851c-5f54-40d3-beee-88b90862f34c">Overactive bladder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Overactive bladder:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used as monotherapy or in combination with an antimuscarinic agent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31039103']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31039103'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral: </b>Initial: 25 mg once daily. May increase to 50 mg once daily after 4 to 8 weeks based on response and tolerability.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991562"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> eGFR may be estimated using the MDRD equation for dosage adjustment purposes (manufacturer’s labeling).</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR ≥30 mL/minute/1.73 m<sup>2</sup>: <b>Oral: </b>No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 15 to &lt;30 mL/minute/1.73 m<sup>2</sup>: <b>Oral: </b>Do not exceed 25 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>: <b>Oral: </b>Not recommended (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly): </b>Unlikely to be dialyzed (large V<sub>d</sub> and moderately high protein binding) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Not recommended (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be dialyzed (large V<sub>d</sub> and relatively high protein binding) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Not recommended (has not been studied).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> Unlikely to be dialyzed (large V<sub>d</sub> and relatively high protein binding) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Not recommended (has not been studied) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> Unlikely to be dialyzed (large V<sub>d</sub> and relatively high protein binding) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Not recommended (has not been studied) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988982"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:2em;">Moderate impairment (Child-Pugh class B): Do not exceed 25 mg once daily.</p>
<p style="text-indent:-2em;margin-left:2em;">Severe impairment (Child-Pugh class C): Not recommended (has not been studied).</p></div>
<div class="block doe drugH1Div" id="F14965740"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F55681972"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="131271" href="/d/html/131271.html" rel="external">see "Mirabegron: Pediatric drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information:</b> Extended-release tablets and extended-release granules are not bioequivalent and cannot be substituted on a mg:mg basis; do not combine dosage forms to achieve a specific dose.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8cfba3c5-bb68-46a2-9ab8-73ec41e1d445">Neurogenic detrusor overactivity</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Neurogenic detrusor overactivity:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥3 years and Adolescents: <b>Note:</b> Appropriate dosage form dependent on patient weight.</p>
<p style="text-indent:-2em;margin-left:6em;">11 to &lt;22 kg: Oral: Granules: Initial: 24 mg once daily; after 4 to 8 weeks of therapy, may increase dose if needed up to a maximum daily dose: 48 mg/<b>day</b> once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">22 to &lt;35 kg: Oral: Granules: Initial: 32 mg once daily; after 4 to 8 weeks of therapy, may increase dose if needed up to a maximum daily dose: 64 mg/<b>day</b> once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">≥35 kg: Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">Granules: Initial: 48 mg once daily; after 4 to 8 weeks of therapy, may increase dose if needed up to a maximum daily dose: 80 mg/<b>day</b> once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">Tablets: Initial: 25 mg once daily; after 4 to 8 weeks of therapy, may increase dose if needed up to a maximum daily dose: 50 mg/<b>day</b> once daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F55681994"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥3 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 30 to 89 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary (regardless of patient weight or dosage form).</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 15 to 29 mL/minute/1.73 m<sup>2</sup>:</p>
<p style="text-indent:-2em;margin-left:6em;">11 to &lt;22 kg: Granules: Do not exceed 24 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">22 to &lt;35 kg: Granules: Do not exceed 32 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">≥35 kg:</p>
<p style="text-indent:-2em;margin-left:8em;">Granules: Do not exceed 48 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">Tablets: Do not exceed 25 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>: Not recommended (has not been studied).</p>
<p style="text-indent:-2em;margin-left:4em;">Hemodialysis: Not recommended (has not been studied).</p></div>
<div class="block dohp drugH1Div" id="F55682004"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥3 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment (Child-Pugh class A): No dosage adjustment necessary (regardless of weight or dosage form).</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate impairment (Child-Pugh class B):</p>
<p style="text-indent:-2em;margin-left:6em;">11 to &lt;22 kg: Granules: Do not exceed 24 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">22 to &lt;35 kg: Granules: Do not exceed 32 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">≥35 kg:</p>
<p style="text-indent:-2em;margin-left:8em;">Granules: Do not exceed 48 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">Tablets: Do not exceed 25 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe impairment (Child-Pugh class C): Not recommended (has not been studied).</p></div>
<div class="block arsc drugH1Div" id="F56005888"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Angioedema</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Angioedema</b> of the face, lips, tongue, and/or larynx has been reported with use of mirabegron (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Davis.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Davis.2019'])">Ref</a></span>); mirabegron-associated angioedema may be life-threatening. Angioedema may be reversible following discontinuation of mirabegron (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Davis.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Davis.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Not clearly established; likely nonallergic (ie, bradykinin-mediated) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Davis.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Davis.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; cases have occurred hours after the first dose or after multiple doses.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Cardiovascular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Dose-related cardiovascular effects have been described with use of mirabegron, including <b>hypertension</b>, <b>tachycardia</b>, and <b>palpitations </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25756594','lexi-content-ref-30203462']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25756594','lexi-content-ref-30203462'])">Ref</a></span>). Changes in cardiovascular parameters associated with mirabegron do not appear to confer an increased risk for adverse cardiovascular events (eg, stroke, myocardial infarction) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29645285','lexi-content-ref-30181042']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29645285','lexi-content-ref-30181042'])">Ref</a></span>). Symptoms may improve or resolve following discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25756594']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25756594'])">Ref</a></span>). Exacerbation of preexisting hypertension has been infrequently reported.</p>
<p style="text-indent:-2em;margin-left:2em;">Oftentimes, increases in blood pressure and heart rate are not clinically significant (eg, systolic blood pressure increased ~3.5/1.5 mm Hg; heart rate increased &lt;5 beats per minute [bpm] following mirabegron 50 mg) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27624693','lexi-content-ref-32975024','lexi-content-ref-30203462','lexi-content-ref-29542337']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27624693','lexi-content-ref-32975024','lexi-content-ref-30203462','lexi-content-ref-29542337'])">Ref</a></span>). In pediatric patients, increases in blood pressure are larger in younger children (ages 3 to &lt;12 years) as compared to older children and adolescents (ages 12 to &lt;18 years). When administered at supratherapeutic doses (ie, 200 mg/day), QTc prolongation was observed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23149929']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23149929'])">Ref</a></span>); however, use of therapeutic doses does not appear to increase the risk of QT prolongation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27624693','lexi-content-ref-31571403','lexi-content-ref-23818156']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27624693','lexi-content-ref-31571403','lexi-content-ref-23818156'])">Ref</a></span>). Mirabegron does not differ with regards to risk of cardiovascular adverse effects when compared to antimuscarinic agents (eg, solifenacin) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29556972','lexi-content-ref-29542337','lexi-content-ref-29645285']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29556972','lexi-content-ref-29542337','lexi-content-ref-29645285'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action. In addition to β<sub>3</sub>-adrenoreceptor (AR) stimulation, mirabegron stimulates β<sub>1</sub>-AR at high doses which may result in positive chronotropic effects, including increased systolic blood pressure and heart rate and decreased stroke volume (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28574581','lexi-content-ref-28618007']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28574581','lexi-content-ref-28618007'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied. Cardiovascular effects were evident during the first month of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27624693']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27624693'])">Ref</a></span>); an ascending-dose study in healthy volunteers noted changes in blood pressure and heart rate within 3 hours of administration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30203462']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30203462'])">Ref</a></span>). In one trial, palpitations developed between 45 minutes and 10 days of initiation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25756594']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25756594'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i> Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• <i>Increased blood pressure:</i></p>
<p style="text-indent:-2em;margin-left:8em;">- Prior history of hypertension (use is not recommended in adult patients with severe uncontrolled hypertension [SBP ≥180 and/or DBP ≥110 mm Hg])</p>
<p style="text-indent:-2em;margin-left:8em;">- Younger children (ages 3 to &lt;12 years) as compared to older children and adolescents (ages 12 to &lt;18 years) (use is not recommended in any pediatric patient with severe uncontrolled hypertension ([SBP and/or DBP &gt;99th percentile plus 5 mm Hg for age, sex, and stature])</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• QT prolongation:</i></p>
<p style="text-indent:-2em;margin-left:8em;">- History of QT interval prolongation or concomitant medications known to prolong the QT interval (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25756594']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25756594'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Urinary retention</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of mirabegron may result in <b>urinary retention</b>, especially in patients with bladder outlet obstruction, benign prostatic hyperplasia (BPH), and/or with use of concomitant muscarinic antagonists (eg, solifenacin, tolterodine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28418102','lexi-content-ref-32761776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28418102','lexi-content-ref-32761776'])">Ref</a></span>). However, in a pooled 12-week analysis of phase III clinical trials, the incidence of urinary retention was negligible in patients treated with mirabegron and changes in postvoid residual volume (PVR) were similar to placebo (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24703195']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24703195'])">Ref</a></span>). In addition, patients receiving mirabegron with risk factors for urinary retention (eg, males, presence of lower urinary tract symptoms, concomitant use of antimuscarinic agents) have been shown to have a low rate of urinary retention or changes in PVR (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28322904','lexi-content-ref-25254938']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28322904','lexi-content-ref-25254938'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Unknown; must also consider the impact of concomitant medications and patient-specific risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16986053','lexi-content-ref-18422378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16986053','lexi-content-ref-18422378'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Bladder outlet obstruction</p>
<p style="text-indent:-2em;margin-left:6em;">• BPH (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32761776']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32761776'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of PVR &gt;200 mL (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28322904']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28322904'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of antimuscarinic agents (eg, solifenacin)</p>
<p style="text-indent:-2em;margin-left:6em;">• Increasing age (eg, risk increases with age ≥40 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16986053']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16986053'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Males (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16986053','lexi-content-ref-18422378']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16986053','lexi-content-ref-18422378'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F15049289"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified. Adverse reactions reported in adults.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Cardiovascular: Hypertension (8% to 11%)<span class="lexi-table-link-container"> (<a aria-label="Hypertension table link" class="lexi-table-link" data-table-id="lexi-content-hypertension" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-hypertension')">table 1</a>)</span><span class="table-link" style="display:none;">Hypertension</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Hypertension" frame="border" id="lexi-content-hypertension" rules="all">
<caption style="text-align:center;">
<b>Mirabegron: Adverse Reaction: Hypertension</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Mirabegron)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Active Control)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Mirabegron)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Active Control)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">11%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">25 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Overactive bladder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">432</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,380</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">9%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">10%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Overactive bladder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">812</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">812</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Overactive bladder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,375</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,380</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Tachycardia (1% to 2%)<span class="lexi-table-link-container"> (<a aria-label="Tachycardia table link" class="lexi-table-link" data-table-id="lexi-content-tachycardia" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-tachycardia')">table 2</a>)</span><span class="table-link" style="display:none;">Tachycardia</span></p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Tachycardia" frame="border" id="lexi-content-tachycardia" rules="all">
<caption style="text-align:center;">
<b>Mirabegron: Adverse Reaction: Tachycardia</b></caption>
<colgroup><col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
<col align="center"/>
</colgroup><thead>
<tr>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Mirabegron)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Comparator (Solifenacin Succinate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Placebo</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Mirabegron)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Solifenacin Succinate)</b></p></th>
<th align="center">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">25 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Overactive bladder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">500</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,288</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">510</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.7%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.8%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Overactive bladder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">500</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,288</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">510</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">25 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Overactive bladder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">432</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,380</p></td></tr>
<tr>
<td align="center">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">0.6%</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">50 mg once daily</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">Overactive bladder</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,375</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">N/A</p></td>
<td align="center">
<p style="text-indent:0em;text-align:left;">1,380</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (1%), constipation (1% to 3%), diarrhea (2%), xerostomia (3% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Cystitis (2%), urinary tract infection (3% to 6%)</p>
<p style="text-indent:-2em;margin-left:4em;">Infection: Influenza (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (1% to 3%), headache (2% to 4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (2%), back pain (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Nasopharyngitis (4%), sinusitis (3%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation, cerebrovascular accident, hypersensitivity angiitis, palpitations</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Genital pruritus, pruritus, skin rash, urticaria</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Increased gamma-glutamyl transferase, increased lactate dehydrogenase</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal distension, dyspepsia, gastritis</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Bladder pain, vaginal infection</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Malignant neoplasm of breast, malignant neoplasm of lung, malignant neoplasm of prostate, purpuric rash</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum alanine aminotransferase, increased serum aspartate aminotransferase</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Osteoarthritis</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Glaucoma</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Nephrolithiasis</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Rhinitis</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined: Ophthalmic: Blurred vision, dry eye syndrome</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Serum sickness-like reaction (Tan 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Urinary retention (Nitti 2014)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (Davis 2019)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Anxiety, confusion, hallucination, insomnia</p></div>
<div class="block coi drugH1Div" id="F14965591"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to mirabegron or any component of the formulation</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Severe uncontrolled hypertension (systolic blood pressure ≥180 mm Hg and/or diastolic blood pressure ≥110 mm Hg); pregnancy</p></div>
<div class="block war drugH1Div" id="F14965598"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Angioedema: Immediately discontinue and institute supportive care if the tongue, hypopharynx, or larynx is involved.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment; dosage adjustment is required in patients with moderate hepatic impairment. Use is not recommended in severe hepatic impairment.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypertension: Use with caution if used in patients with controlled and less severe hypertension; use is not recommended in patients with uncontrolled hypertension.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment; dosage adjustment is required in patients with severe renal impairment. Use is not recommended in ESRD.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Product interchangeability: ER granules and ER tablets are not interchangeable; do not combine products to achieve a total dose. Select appropriate product based on patient's indication and weight; ER granules are not approved for adult use (recommended dose not determined).</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F55679742"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Increased blood pressure may occur in patients treated with mirabegron; increases are larger in younger children (ages 3 to &lt;12 years) compared to older children and adolescents (12 to &lt;18 years). Use is not recommended in pediatric patients with severe uncontrolled hypertension (SBP and/or DBP &gt;99th percentile plus 5 mm Hg for age, sex, and stature).</p></div>
<div class="block foc drugH1Div" id="F15167820"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Suspension Reconstituted ER, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Myrbetriq: 8 mg/mL (100 mL) [contains ethylparaben, methylparaben]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Myrbetriq: 25 mg, 50 mg</p></div>
<div class="block geq drugH1Div" id="F14965578"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16570442"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Suspension Reconstituted ER</b> (Myrbetriq Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">8 mg/mL (per mL): $2.77</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, 24-hour</b> (Myrbetriq Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $18.41</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $18.41</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52871459"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release 24 Hour, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Myrbetriq: 25 mg, 50 mg</p></div>
<div class="block adm drugH1Div" id="F14965840"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer tablet without regard to food; swallow whole with water; do not chew, divide, or crush.</p>
<p style="text-indent:-2em;margin-left:2em;">Bariatric surgery: Tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. No IR formulation is available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery.</p></div>
<div class="block admp drugH1Div" id="F55682006"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral:</p>
<p style="text-indent:-2em;margin-left:2em;">Granules: Administer with food. Before use, shake bottle for 1 minute, then let stand until foam has been dissipated (~1 to 2 minutes). Measure dose using an accurate measuring device; use dose within 1 hour of measuring. If mirabegron will not be used for ≥2 days, bottle should be shaken vigorously for 1 minute each day not used.</p>
<p style="text-indent:-2em;margin-left:2em;">Tablets: Administer with food in pediatric patients. Swallow the tablet whole with water; do not chew, divide, or crush.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>Missed dose:</i> Administer dose as soon as remembered if ≤12 hours since missed dose; if &gt;12 hours have passed, skip dose and administer next dose at usual time.</p></div>
<div class="block use drugH1Div" id="F14585330"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Neurogenic detrusor overactivity:</b> Treatment of neurogenic detrusor overactivity in pediatric patients ≥3 years of age (granules) and weighing ≥35 kg (tablets).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Overactive bladder:</b> Treatment of overactive bladder in adults with symptoms of urinary frequency, urgency, or urge urinary incontinence as monotherapy or in combination with an antimuscarinic agent (AUA/SUFU [Gormley 2019]).</p></div>
<div class="block cyt drugH1Div" id="F15163957"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2D6 (minor), CYP3A4 (minor), OCT1, OCT2, P-glycoprotein/ABCB1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2D6 (moderate)</p></div>
<div class="block dri drugH1Div" id="F15163955"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Ajmaline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amitriptyline: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Amitriptyline. CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amitriptyline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amoxapine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amoxapine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Amphetamines.  Management: Monitor for amphetamine toxicities (including serotonin syndrome) if used with a moderate CYP2D6 inhibitor. Initiate amphetamine therapy at lower doses, monitor frequently, and adjust doses as needed. Discontinue amphetamines if serotoinin syndrome occurs<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticholinergic Agents: May enhance the adverse/toxic effect of Mirabegron.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy, indication, or dosage form. Consult full interaction monograph for specific recommendations.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ARIPiprazole Lauroxil: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of ARIPiprazole Lauroxil. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atomoxetine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Atomoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexpiprazole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Brexpiprazole.  Management: If brexpiprazole is to be used together with both a moderate CYP2D6 inhibitor and a strong or moderate CYP3A4 inhibitor, the brexpiprazole dose should be reduced to 25% of the usual dose when treating indications other than major depressive disorder.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carvedilol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Carvedilol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">ClomiPRAMINE: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of ClomiPRAMINE. CYP2D6 Inhibitors (Moderate) may increase the serum concentration of ClomiPRAMINE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Codeine: CYP2D6 Inhibitors (Moderate) may diminish the therapeutic effect of Codeine. These CYP2D6 inhibitors may prevent the metabolic conversion of codeine to its active metabolite morphine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Mirabegron.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desipramine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Desipramine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deutetrabenazine: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Deutetrabenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dextromethorphan: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Dextromethorphan. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Digoxin: Mirabegron may increase the serum concentration of Digoxin.  Management: Consider initiating the lowest dose of digoxin in patients beginning treatment with a combination of digoxin and mirabegron. Monitor digoxin concentrations and adjust the digoxin dose as needed.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxepin (Systemic): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Doxepin (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxepin (Topical): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Doxepin (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">DOXOrubicin (Conventional): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of DOXOrubicin (Conventional). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eliglustat: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Eliglustat.  Management: Eliglustat dose is 84 mg daily with CYP2D6 inhibitors. Use is contraindicated (COI) when also combined with strong CYP3A4 inhibitors. When also combined with a moderate CYP3A4 inhibitor, use is COI in CYP2D6 EMs or IMs and should be avoided in CYP2D6 PMs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fesoterodine: Mirabegron may enhance the adverse/toxic effect of Fesoterodine. Mirabegron may increase serum concentrations of the active metabolite(s) of Fesoterodine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Flecainide: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Flecainide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iboga: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Iboga. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Iloperidone: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P95 may be decreased. CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolite P88 may be increased. CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Iloperidone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Imipramine: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Imipramine. Concentrations of desipramine may be increased. CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Imipramine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indoramin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Indoramin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lofepramine: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Lofepramine. The active metabolite of lofepramine is desipramine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mequitazine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Mequitazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Methadone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Metoclopramide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoprolol: Mirabegron may diminish the antihypertensive effect of Metoprolol. Mirabegron may increase the serum concentration of Metoprolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nebivolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nebivolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nortriptyline: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Nortriptyline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oliceridine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Oliceridine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Olmutinib: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Olmutinib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">PARoxetine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of PARoxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perhexiline: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Perhexiline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Perphenazine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Perphenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Pimozide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pitolisant: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Pitolisant. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propafenone: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Propafenone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Propranolol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Propranolol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Protriptyline: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Protriptyline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">RisperiDONE: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of RisperiDONE. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sertindole: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Sertindole. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Solifenacin: Mirabegron may enhance the adverse/toxic effect of Solifenacin. Specifically, the risk of acute urinary retention may be enhanced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamoxifen: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of Tamoxifen. Specifically, CYP2D6 inhibitors may decrease the metabolic formation of highly potent active metabolites.  Management: Consider alternatives to the use of moderate CYP2D6 inhibitors with tamoxifen when possible, as the combination may be associated with reduced clinical effectiveness of tamoxifen.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tamsulosin: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Tamsulosin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetrabenazine: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Tetrabenazine. Specifically, concentrations of the active alpha- and beta-dihydrotetrabenazine metabolites may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Thioridazine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Timolol (Systemic): CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Timolol (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: CYP2D6 Inhibitors (Moderate) may decrease serum concentrations of the active metabolite(s) of TraMADol. CYP2D6 Inhibitors (Moderate) may increase the serum concentration of TraMADol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Trimipramine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Trimipramine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Valbenazine: CYP2D6 Inhibitors (Moderate) may increase serum concentrations of the active metabolite(s) of Valbenazine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vortioxetine: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Vortioxetine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zuclopenthixol: CYP2D6 Inhibitors (Moderate) may increase the serum concentration of Zuclopenthixol. <i> Risk C: Monitor therapy</i></p></div>
<div class="block pri drugH1Div" id="F14965585"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;display:inline">Adverse effects have been observed in some animal reproduction studies.</p></div>
<div class="block brc drugH1Div" id="F14965590"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:0em;display:inline">It is not known if mirabegron is present in breast milk. According to the manufacturer, the decision to continue or discontinue breastfeeding during therapy should take into account the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother.</p></div>
<div class="block mop drugH1Div" id="F14965843"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Monitor BP at baseline and then periodically during therapy (especially in patients with preexisting hypertension, even if controlled); postvoid residual urine volume at baseline and as clinically indicated thereafter (AUA [Lerner 2021]); signs and symptoms of urinary retention.</p></div>
<div class="block pha drugH1Div" id="F14965672"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Mirabegron, a beta-3 adrenergic receptor agonist, activates beta-3 adrenergic receptors in the bladder resulting in relaxation of the detrusor smooth muscle during the urine storage phase, thus increasing bladder capacity. At usual doses, mirabegron is believed to display selectivity for the beta-3 adrenergic receptor subtype compared to its affinity for the beta-1 and -2 adrenoceptor subtypes. Data have shown that beta-adrenoceptors, predominately the beta-3 subtype, mediate detrusor smooth muscle tone and promote the storage function of the human bladder.</p></div>
<div class="block phk drugH1Div" id="F14965682"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Adults: Overactive bladder: Efficacy is seen within 8 weeks; steady state achieved within 7 days.</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption:</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Tablets: No clinically significant differences with fed vs fasting administration.</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥3 years and Adolescents:</p>
<p style="text-indent:-2em;margin-left:6em;">Granules: Fasting AUC increased by 170% and C<sub>max</sub> increased by 80% compared to fed state.</p>
<p style="text-indent:-2em;margin-left:6em;">Tablets: Fasting AUC increased by 120% compared to fed state.</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution:</p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric patients: Vz/F: Large mean range reported: 4,895 to 13,726 L.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: V<sub>ss</sub>: ~1,670 L (following IV administration).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: ~71%; binds mainly to albumin and alpha<sub>1</sub>-acid glycoprotein.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Extensive metabolism via multiple pathways (eg, dealkylation, oxidation, glucuronidation, amide hydrolysis) via multiple enzymes (eg, UGT, esterase, CYP3A4, CYP2D6); two major pharmacologically inactive metabolites produced.</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: 29% to 35% (following 25 mg and 50 mg oral dosing, respectively); bioavailability is dose-dependent; C<sub>max</sub> and AUC are higher in females compared to males.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination:</p>
<p style="text-indent:-2em;margin-left:4em;">Pediatric patients: ~26 to 31 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: ~50 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak:</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥3 years and Adolescents: Granules, Tablets: Fed-state: Median: 4 to 5 hours (single dose), 3 to 4 hours (steady-state; predicted).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults: Tablets: ~3.5 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (radiolabeled drug: 55%; unchanged drug: ~25%); feces (radiolabeled drug: 34%; unchanged drug: 0%).</p></div>
<div class="block phksp drugH1Div" id="F51159617"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: Following single dose administration of mirabegron 100 mg in adults with mild renal impairment (eGFR 60 to 89 mL/minute/1.73 m<sup>2</sup> as estimated by modification of diet in renal disease), mean mirabegron C<sub>max</sub> and AUC were increased by 6% and 31% relative to adults with normal renal function. In adults with moderate renal impairment (eGFR 30 to 59 mL/minute/1.73 m<sup>2</sup>), C<sub>max</sub> and AUC were increased by 23% and 66%, respectively. In adults with severe renal impairment (eGFR 15 to 29 mL/minute/1.73 m<sup>2</sup>), mean C<sub>max</sub> and AUC values were 92% and 118% higher compared with healthy subjects with normal renal function.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic impairment: Following single-dose administration of mirabegron 100 mg in adults with mild hepatic impairment (Child-Pugh class A), mean mirabegron C<sub>max</sub> and AUC were increased by 9% and 19% relative to adults with normal hepatic function. In adults with moderate hepatic impairment (Child-Pugh class B), mean C<sub>max</sub> and AUC values were 175% and 65% higher.</p>
<p style="text-indent:-2em;margin-left:2em;">Sex: The C<sub>max</sub> and AUC of mirabegron were ~40% to 50% higher in adult females than in adult males. When corrected for differences in body weight, the mirabegron systemic exposure is 20% to 30% higher in adult females compared with adult males.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F14721653"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Urgistat | Uroval</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Betmira er | Iragon | Mirabeg | Mirader | Mirasol xr | Utromeg</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Myrbetric</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Betmiga | Myrbetric</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Urgistat</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Atobegron | Betmiga | Bladogra | Uribladon xr</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Betmiga | Bladmir | Exena | Megatas | Mira | Mirabet | Mirabig | Mirago | Mirakem | Miranix | Mirasmart | Miratas | Mirbeg | Vesibeta</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Betanis</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Betagron | Betmiga | Br mirabegron ir | Gitamiga sr | Liberon | Mira q ron | Mirabe sr | Mirabeg sr | Miraron | Ql pharma mirabegron | Rabegron | Rablon sr | Selebeta sr | Tamiga</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Myrbetric</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Myrbetric</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Begron | Mibega | Mirabet | Mirexia xr</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Myrbetriq</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Betmiga</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-25756594">
<a name="25756594"></a>Balachandran AA, Duckett JR. The risk and severity of developing symptomatic palpitations when prescribed mirabegron for overactive bladder. <i>Eur J Obstet Gynecol Reprod Biol</i>. 2015;187:60-63. doi:10.1016/j.ejogrb.2015.02.020<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/25756594/pubmed" id="25756594" target="_blank">25756594</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29556972">
<a name="29556972"></a>Chen HL, Chen TC, Chang HM, et al. Mirabegron is alternative to antimuscarinic agents for overactive bladder without higher risk in hypertension: a systematic review and meta-analysis. <i>World J Urol</i>. 2018;36(8):1285-1297. doi:10.1007/s00345-018-2268-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/29556972/pubmed" id="29556972" target="_blank">29556972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Davis.2019">
<a name="Davis.2019"></a>Davis, Harley &amp; Wallace, MD &amp; Gilkerson, Christine &amp; Saunders, Elizabeth. (2019). Drug-induced Angioedema: A Rare Side Effect of Mirabegron. <i>West Virginia Medical Journal</i>. 2019. doi:10.21885/wvmj.2019.5</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28322904">
<a name="28322904"></a>Drake MJ, MacDiarmid S, Al-Shukri S, et al. Adding mirabegron to solifenacin to treat overactive bladder has little impact on postvoid residual volume or urinary retention risk. <i>Urology</i>. 2017;104:1-4. doi:10.1016/j.urology.2017.03.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/28322904/pubmed" id="28322904" target="_blank">28322904</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23098785">
<a name="23098785"></a>Gormley EA, Lightner DJ, Burgio KL, et al; American Urological Association; Society of Urodynamics, Female Pelvic Medicine &amp; Urogenital Reconstruction. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline. <i>J Urol. 2</i>012;188(6)(suppl):S2455-S2463. doi:10.1016/j.juro.2012.09.079<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/23098785/pubmed" id="23098785" target="_blank">23098785</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28418102">
<a name="28418102"></a>Herschorn S, Chapple CR, Abrams P, et al. Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). <i>BJU Int</i>. 2017;120(4):562-575. doi:10.1111/bju.13882<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/28418102/pubmed" id="28418102" target="_blank">28418102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25254938">
<a name="25254938"></a>Ichihara K, Masumori N, Fukuta F, Tsukamoto T, Iwasawa A, Tanaka Y. A randomized controlled study of the efficacy of tamsulosin monotherapy and its combination with mirabegron for overactive bladder induced by benign prostatic obstruction. <i>J Urol</i>. 2015;193(3):921-926. doi:10.1016/j.juro.2014.09.091<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/25254938/pubmed" id="25254938" target="_blank">25254938</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31571403">
<a name="31571403"></a>Katoh T, Igawa Y, Yamaguchi O, Kato D, Hamada T, Kuroishi K. Cardiovascular safety of antimuscarinic add-on therapy in patients with overactive bladder who had a suboptimal response to mirabegron monotherapy: A post hoc analysis from the Japanese MILAI II study. <i>Low Urin Tract Symptoms</i>. 2020;12(1):68-80. doi:10.1111/luts.12286<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/31571403/pubmed" id="31571403" target="_blank">31571403</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32975024">
<a name="32975024"></a>Katoh T, Kakizaki H, Lee KS, et al. Cardiovascular safety of mirabegron add-on therapy to tamsulosin for the treatment of overactive bladder in men with lower urinary tract symptoms: A post hoc analysis from the MATCH study. <i>Low Urin Tract Symptoms</i>. 2021;13(1):98-107. doi:10.1111/luts.12339<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/32975024/pubmed" id="32975024" target="_blank">32975024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27624693">
<a name="27624693"></a>Katoh T, Kuwamoto K, Kato D, Kuroishi K. Real-world cardiovascular assessment of mirabegron treatment in patients with overactive bladder and concomitant cardiovascular disease: Results of a Japanese post-marketing study. <i>Int J Urol</i>. 2016;23(12):1009-1015. doi:10.1111/iju.13218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/27624693/pubmed" id="27624693" target="_blank">27624693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34384237">
<a name="34384237"></a>Lerner LB, McVary KT, Barry MJ, et al. Management of lower urinary tract symptoms attributed to benign prostatic hyperplasia: AUA guideline part I, initial work-up and medical management. <i>J Urol</i>. 2021;206(4):806-817. doi:10.1097/JU.0000000000002183<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/34384237/pubmed" id="34384237" target="_blank">34384237</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31039103">
<a name="31039103"></a>Lightner DJ, Gomelsky A, Souter L, Vasavada SP. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment 2019. <i>J Urol</i>. 2019;202(3):558-563. doi:10.1097/JU.0000000000000309<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/31039103/pubmed" id="31039103" target="_blank">31039103</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30203462">
<a name="30203462"></a>Loh RKC, Formosa MF, La Gerche A, Reutens AT, Kingwell BA, Carey AL. Acute metabolic and cardiovascular effects of mirabegron in healthy individuals. <i>Diabetes Obes Metab</i>. 2019;21(2):276-284. doi:10.1111/dom.13516<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/30203462/pubmed" id="30203462" target="_blank">30203462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23149929">
<a name="23149929"></a>Malik M, van Gelderen EM, Lee JH, et al. Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study. <i>Clin Pharmacol Ther</i>. 2012;92(6):696-706.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/23149929/pubmed" id="23149929" target="_blank">23149929</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21510978">
<a name="21510978"></a>Michel MC, Ochodnicky P, Homma Y, et al. β-adrenoceptor agonist effects in experimental models of bladder dysfunction. <i>Pharmacol Ther.</i> 2011;131(1):40-49.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/21510978/pubmed" id="21510978" target="_blank">21510978</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28574581">
<a name="28574581"></a>Mo W, Michel MC, Lee XW, Kaumann AJ, Molenaar P. The β<sub>3</sub> -adrenoceptor agonist mirabegron increases human atrial force through β<sub>1</sub> -adrenoceptors: an indirect mechanism? <i>Br J Pharmacol</i>. 2017;174(16):2706-2715. doi:10.1111/bph.13897<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/28574581/pubmed" id="28574581" target="_blank">28574581</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Myrbetriq.1">
<a name="Myrbetriq.1"></a>Myrbetriq (mirabegron) [prescribing information]. Northbrook, IL: Astellas Pharma US Inc; April 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Myrbetriq.2">
<a name="Myrbetriq.2"></a>Myrbetriq (mirabegron) [product monograph]. Markham, ON, Canada: Astellas Pharma Canada Inc; June 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24703195">
<a name="24703195"></a>Nitti VW, Chapple CR, Walters C, et al. Safety and tolerability of the β3 -adrenoceptor agonist mirabegron, for the treatment of overactive bladder: results of a prospective pooled analysis of three 12-week randomised Phase III trials and of a 1-year randomised Phase III trial. <i>Int J Clin Pract</i>. 2014;68(8):972-985. doi:10.1111/ijcp.12433<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/24703195/pubmed" id="24703195" target="_blank">24703195</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16986053">
<a name="16986053"></a>Roehrborn CG. Acute urinary retention: risks and management. <i>Rev Urol</i>. 2005;7 suppl 4(suppl 4):S31-S41.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/16986053/pubmed" id="16986053" target="_blank">16986053</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29542337">
<a name="29542337"></a>Rosa GM, Baccino D, Valbusa A, et al. Cardiovascular effects of antimuscarinic agents and beta3-adrenergic receptor agonist for the treatment of overactive bladder. <i>Expert Opin Drug Saf</i>. 2018;17(5):487-497. doi:10.1080/14740338.2018.1453496<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/29542337/pubmed" id="29542337" target="_blank">29542337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23818156">
<a name="23818156"></a>Sanford M. Mirabegron: a review of its use in patients with overactive bladder syndrome. <i>Drugs</i>. 2013;73(11):1213-1225.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/23818156/pubmed" id="23818156" target="_blank">23818156</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32761776">
<a name="32761776"></a>Takahashi S, Kato D, Tabuchi H, Uno S. Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post-marketing study. <i>Low Urin Tract Symptoms</i>. 2021;13(1):79-87. doi:10.1111/luts.12335<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/32761776/pubmed" id="32761776" target="_blank">32761776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31205999">
<a name="31205999"></a>Tan MG, Burns BF, Glassman SJ. Serum sickness-like reaction associated with mirabegron. <i>JAAD Case Rep</i>. 2019;5(6):537-539. doi:10.1016/j.jdcr.2019.04.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/31205999/pubmed" id="31205999" target="_blank">31205999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28618007">
<a name="28618007"></a>van Gelderen M, Stölzel M, Meijer J, Kerbusch V, Collins C, Korstanje C. An exploratory study in healthy male subjects of the mechanism of mirabegron-induced cardiovascular effects. <i>J Clin Pharmacol</i>. 2017;57(12):1534-1544. doi:10.1002/jcph.952<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/28618007/pubmed" id="28618007" target="_blank">28618007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18422378">
<a name="18422378"></a>Verhamme KM, Sturkenboom MC, Stricker BH, Bosch R. Drug-induced urinary retention: incidence, management and prevention. <i>Drug Saf</i>. 2008;31(5):373-388. doi:10.2165/00002018-200831050-00002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/18422378/pubmed" id="18422378" target="_blank">18422378</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29645285">
<a name="29645285"></a>White WB, Chapple C, Gratzke C, et al. Cardiovascular safety of the β<sub>3</sub> -adrenoceptor agonist mirabegron and the antimuscarinic agent solifenacin in the SYNERGY trial. <i>J Clin Pharmacol</i>. 2018;58(8):1084-1091. doi:10.1002/jcph.1107<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/29645285/pubmed" id="29645285" target="_blank">29645285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30181042">
<a name="30181042"></a>White WB, Siddiqui E, Tat T, Franks B, Schermer CR. Cardiovascular safety of mirabegron: analysis of an integrated clinical trial database of patients with overactive bladder syndrome. <i>J Am Soc Hypertens</i>. 2018;12(11):768-778.e1. doi:10.1016/j.jash.2018.08.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/mirabegron-drug-information/abstract-text/30181042/pubmed" id="30181042" target="_blank">30181042</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 85675 Version 228.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
